Abstract
The persistence of the motivational salience of drug-related environmental cues and contexts is one of the most problematic obstacles to successful treatment of drug addiction. Behavioral approaches to extinguishing the salience of drug-associated cues, such as cue exposure therapy, have generally produced disappointing results which have been attributed to, among other things, the context specificity of extinction and inadequate consolidation of extinction learning. Extinction of any behavior or conditioned response is a process of new and active learning, and increasing evidence suggests that glutamatergic neurotransmission, a key component of the neural plasticity that underlies normal learning and memory, is also involved in extinction learning. This review will summarize findings from both animal and human studies that suggest that pharmacological enhancement of glutamatergic neurotransmission facilitates extinction learning in the context of drug addiction. Pharmacological agents that have shown potential efficacy include NMDA partial agonists, mGluR5 receptor positive allosteric modulators, inhibitors of the GlyT1 glycine transporter, AMPA receptor potentiators, and activators of the cystine-glutamate exchanger. These classes of cognition-enhancing compounds could potentially serve as novel pharmacological adjuncts to cue exposure therapy to increase success rates in attenuating cue-induced drug craving and relapse.
Keywords: Extinction, learning, glutamate, NMDA, AMPA, mGluR5, GlyT1 glycine transporter, receptor potentiator, allosteric modulator, cystine-glutamate exchanger, Drug addiction, compulsive drug intake, drug-seeking, intake. Chronic, drug's effects, drug craving, hyper-salient, drug-related stimuli, neural circuits, long-term potentiation, long-term depression, neurotransmission, hyperexcitability, excito-toxicity, neuroanatomical substrates, synaptic plasticity, D-cycloserine, anxiety disorders, de novo protein synthesis, intracellular signaling, pro-mnemonic, N-methyl-D-asparate, baso-lateral amygdala, drug-associated, animal models, conditioned place preference, intra-venous drug self-administration, indwelling intravenous catheter, reinstatement, prefrontal cortex, campus, amygdala, amphetamine, cocaine-induced reinstatement, glutamatergic synapse, ionotropic gluta-mate receptors, methylisoxazole-4-propionic acid, kainic acid, D-serine, glycine, GlyT1, GlyT2, GluRA-D, GluR1, mGluRs, GPCRs, excitatory amino acid transport-ers (EAATs), excitotoxicity, fluorobenzylidene, dioxoisoindolin-2
Current Neuropharmacology
Title: Glutamatergic Targets for Enhancing Extinction Learning in Drug Addiction
Volume: 8 Issue: 4
Author(s): R. M. Cleva, J. T. Gass, J. J. Widholm and M. F. Olive
Affiliation:
Keywords: Extinction, learning, glutamate, NMDA, AMPA, mGluR5, GlyT1 glycine transporter, receptor potentiator, allosteric modulator, cystine-glutamate exchanger, Drug addiction, compulsive drug intake, drug-seeking, intake. Chronic, drug's effects, drug craving, hyper-salient, drug-related stimuli, neural circuits, long-term potentiation, long-term depression, neurotransmission, hyperexcitability, excito-toxicity, neuroanatomical substrates, synaptic plasticity, D-cycloserine, anxiety disorders, de novo protein synthesis, intracellular signaling, pro-mnemonic, N-methyl-D-asparate, baso-lateral amygdala, drug-associated, animal models, conditioned place preference, intra-venous drug self-administration, indwelling intravenous catheter, reinstatement, prefrontal cortex, campus, amygdala, amphetamine, cocaine-induced reinstatement, glutamatergic synapse, ionotropic gluta-mate receptors, methylisoxazole-4-propionic acid, kainic acid, D-serine, glycine, GlyT1, GlyT2, GluRA-D, GluR1, mGluRs, GPCRs, excitatory amino acid transport-ers (EAATs), excitotoxicity, fluorobenzylidene, dioxoisoindolin-2
Abstract: The persistence of the motivational salience of drug-related environmental cues and contexts is one of the most problematic obstacles to successful treatment of drug addiction. Behavioral approaches to extinguishing the salience of drug-associated cues, such as cue exposure therapy, have generally produced disappointing results which have been attributed to, among other things, the context specificity of extinction and inadequate consolidation of extinction learning. Extinction of any behavior or conditioned response is a process of new and active learning, and increasing evidence suggests that glutamatergic neurotransmission, a key component of the neural plasticity that underlies normal learning and memory, is also involved in extinction learning. This review will summarize findings from both animal and human studies that suggest that pharmacological enhancement of glutamatergic neurotransmission facilitates extinction learning in the context of drug addiction. Pharmacological agents that have shown potential efficacy include NMDA partial agonists, mGluR5 receptor positive allosteric modulators, inhibitors of the GlyT1 glycine transporter, AMPA receptor potentiators, and activators of the cystine-glutamate exchanger. These classes of cognition-enhancing compounds could potentially serve as novel pharmacological adjuncts to cue exposure therapy to increase success rates in attenuating cue-induced drug craving and relapse.
Export Options
About this article
Cite this article as:
M. Cleva R., T. Gass J., J. Widholm J. and F. Olive M., Glutamatergic Targets for Enhancing Extinction Learning in Drug Addiction, Current Neuropharmacology 2010; 8 (4) . https://dx.doi.org/10.2174/157015910793358169
DOI https://dx.doi.org/10.2174/157015910793358169 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
The Role of Neurotrophins in Axonal Growth, Guidance, and Regeneration
Current Neurovascular Research Lipid Nanocarriers and Molecular Targets for Malaria Chemotherapy
Current Drug Targets TRPC Channels and their Implications for Neurological Diseases
CNS & Neurological Disorders - Drug Targets The Paths to Neurodegeneration in Genetic Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Trait vs. State Markers for Schizophrenia: Identification and Characterization Through Visual Processes
Current Psychiatry Reviews Allosteric Modulation of Nicotinic Acetylcholine Receptors: The Concept and Therapeutic Trends
Current Pharmaceutical Design GABAA Receptors in Normal Development and Seizures: Friends or Foes?
Current Neuropharmacology Oligomerization of the Heptahelical G Protein Coupling Receptors: A Case for Association Using Transmembrane Helices (Supplimentry Material)
Mini-Reviews in Medicinal Chemistry Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA)
Current Neuropharmacology Noninvasive Monitoring of Intracranial Pressure
Recent Patents on Biomedical Engineering (Discontinued) Chemistry and Pharmacological Properties of Some Natural and Synthetic Antioxidants for Heavy Metal Toxicity
Current Medicinal Chemistry Molecular Pharmacology of the Glycine Receptor Chloride Channel
Current Pharmaceutical Design Overview of Pediatric Epilepsy
Current Pediatric Reviews Beta-Caryophyllene, a CB2R Selective Agonist, Protects Against Cognitive Impairment Caused by Neuro-inflammation and Not in Dementia Due to Ageing Induced by Mitochondrial Dysfunction
CNS & Neurological Disorders - Drug Targets Phosphodiesterase Inhibitors as a Target for Cognition Enhancement in Aging and Alzheimer’s Disease: A Translational Overview
Current Pharmaceutical Design State Dissociation, Human Behavior, and Consciousness
Current Topics in Medicinal Chemistry The Brainstem Tau Cytoskeletal Pathology of Alzheimer’s Disease: A Brief Historical Overview and Description of its Anatomical Distribution Pattern, Evolutional Features, Pathogenetic and Clinical Relevance
Current Alzheimer Research Glutamate and Psychosis Risk
Current Pharmaceutical Design Neurotrophic Factors in Combination: A Possible new Therapeutic Strategy to Influence Pathophysiology of Spinal Cord Injury and Repair Mechanisms
Current Pharmaceutical Design Lifestyle and Genetic Contributions to Cognitive Decline and Hippocampal Structure and Function in Healthy Aging
Current Alzheimer Research